Compare Intel Corp (INTC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Intel Corp trades at $95.48 (market cap $543.46B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Intel Corp is far larger — about 72.3× Spyre Therapeutics Inc. Common Stock's market cap, and Intel Corp pays a 2.24% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| INTC | SYRE | |
|---|---|---|
Market Cap | $543.46B | $7.52B |
Volume | 87,420,405 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $140.94 | $108.92 |
52-Week Low | $33.62 | $22.18 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $564.27B | $6.52B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $102.81, up 1.44% with strong recent earnings beats but faces fundamental challenges including negative net income margin of -19.79% and elevated P/E ratio of 904.17. The stock has shown impressive 2026 momentum with three consecutive quarterly EPS beats, while technical indicators show mixed signals with bearish moving averages but bullish oscillators. Recent news highlights Intel's foundry turnaround efforts and 220% stock surge in 2026, though competition remains intense.
Intel presents a turnaround story with significant execution risks. The foundry business shows growth potential with 31% revenue increase, but negative profitability metrics and high valuation ratios suggest caution. Analyst consensus leans neutral with 54% hold ratings, while the $111.72 price target offers modest upside. Key risks include competitive pressures from TSMC and AMD, margin challenges, and the sustainability of recent stock gains.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
